tbuckley/cabot-search huggingface dataset:
SCDT-08. INJECTABLE DIBLOCK COPOLYPEPTIDE HYDROGEL PROVIDES A PROLONGED LOCAL DEPOT OF PACLITAXEL THAT PROVIDES LOCAL TUMOR CONTROL IN A PATIENT-DERIVED XENOTRANSPLANT MODEL OF GLIOBLASTOMA
Authors: Matthew Garrett, Timothy O’Shea, Alexander Bernstein, Alexander Wollenberg, Derek Hung, Timothy Deming, Harley Kornblum, Michael Sofroniew
Journal: Neuro-Oncology (2017)

The treatment of glioblastoma is limited by the fact that most oral/IV chemotherapy regimens are not able to cross the blood-brain barrier. While previous studies have designed modalities to directly deliver chemotherapeutic compounds in situ, few if any of these studies directly tested these modalities in a realistic in vivo system. In this study we investigate a minimally invasive carrier system that delivers potent amounts of any chemotherapeutic compound in an intracranial xeno-transplant model using patient-derived glioblastoma cells. We tested the ability of a diblock copolypeptide hydrogel (DCH) to deliver an effective dose of paclitaxel to an in vivo xenotransplantation model of glioblastoma to extend survival. Additionally we examined the biocompatibility of our paclitaxel-loaded gel on brain tissue compared against Cremaphore (the usual carrier agent of Paclitaxel) in terms of inflammatory reaction and reactive gliosis. Finally we examined the effect of our local delivery on tumor migration. DCH loaded with high concentrations of paclitaxel formed a deposit upon injection into the mouse forebrain and demonstrated persistent drug concentrations within 100-200µm of the material-tissue interface for at least 4 weeks. The DCH-paclitaxel system caused minimal healthy host tissue disruption and displayed an improved foreign body response compared Cremophor. DCH-paclitaxel treatment facilitated a near four-fold ablation of the initial locally residing glioblastoma cell population compared to DCH only control, conferring a significant increase in median survival time of 2.5 weeks, representing a 22.7% extension of survival time. However mice treated with DCH-paclitaxel gels showed tumor cells that had migrated to deeper levels of the brain compared to control gels. Direct delivery systems of hydrophobic compounds provide an avenue to deliver much more effective chemotherapy to primary brain tumors. While this hydrogel provided local tumor control, tumor cells were able to migrate away from the treated area.
EXTH-06. A CANCER DRUG-ATLAS ENABLES PREDICTION OF PARALLEL DRUG VULNERABILITIES
Authors: Ravi Narayan, Piet Molenaar, Fleur Cornelissen, Irene Roelofs, Peter Sminia, Thomas Wurdinger, Jan Koster, Bart Westerman
Journal: Neuro-Oncology (2017)

Personalized cancer treatments using synergistic combinations of drugs is attractive but proves to be highly challenging. The combinatorial nature of such problems results in an enormous parameter-space that cannot be resolved by empirical research, i.e. testing all combinations for all molecularly defined tumors. In addition, effective drug-synergy is hard to predict. Here we present a topology-based approach to map data of drug-response encyclopedias and represent these as a drug-atlas. This atlas consists of a framework of chemotherapeutic responses that represents a drug-vulnerability landscape of cancer. Based on data from the literature we found that many synergistic drug combinations show distinct inter-therapy responses and drug-sensitivities. We confirmed this by performing a drug-combination screen against glioblastoma where we used 270 combination experiments. From the identified dual-therapies we were able to predict and validate a triple-drug synergy which was validated in vivo. This new and generalizable strategy opens the door to unforeseen personalized multi-drug combination approaches against glioblastoma.
NIMG-24. PATHOLOGY CONFIRMED RADIOGRAPHIC DIAGNOSIS OF TRUE PROGRESSION AND PSEUDO-PROGRESSION MADE BY ADVANCED BRAIN TUMOR IMAGING
Authors: Raul F Valenzuela, Laura Ocasio, Meenakshi B Bhattacharjee, Guangrong Lu, Mayank Rao, Nitin Tandon, Yoshua Esquenazi, Jay-Jiguang Zhu, Roy Riascos-Castaneda
Journal: Neuro-Oncology (2017)

PURPOSEDifferentiation of true tumor progression verse pseudo-pregresion in glioblastomas patients by routine MRI is a challenging task, in part because T1 enhancement and timeline similarities where pseudo-progression can happen within first 3-6 months post chemoradiation. We performed a retrospective data analysis of Advanced Brain Tumor Imaging (ABTI) protocol as a differentiating tool.
P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy as 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)
Authors: S. Ren, G. Gao, W. Li, X. Chen, F. Wu, C. Su, J. Zhao, Y. Sun, W. Cai, C. Zhou
Journal: Journal of Thoracic Oncology (2017)
P3.02-028 276 Cases of EGFR/ALK Gene Status and Predominant Histologic Subtype in Chinese Surgically Resected Lung Adenocarcinoma
Authors: Z. Huang, C. Xu, W. Wang, W. Zhuang, Z. Song, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2017)
ANGI-02. INHIBITION OF APLN-APLNR SIGNALLING BLOCKS TUMOUR ANGIOGENESIS AND ATTENUATES INVASIVE GLIOBLASTOMA GROWTH
Authors: Rainer Glass, Giorgia Mastrella, Mengzhuo Hou, Veit Stöcklein, Hrvoje Miletic, Christel Herold-Mende, Michael Synowitz, Angelo Vescovi, Rolf Bjerkvig, Ulrich Schüller, Joerg-Christian Tonn, Roland Kaelin
Journal: Neuro-Oncology (2017)

Glioblastoma multiforme (GBM) present with an abundant tumour neo-vasculature and a high degree of tumour cell infiltration into the parenchyma. In a serial implantation model recapitulating the angiogenic switch of human GBM we found that the expression levels of the proangiogenic receptor APLNR and its cognate ligand APLN strongly increase with the onset of tumour-vascularisation. Screening a set of murine and human GBM stem cell (GSC) cultures of different genetic subtypes we consistently detected APLN/APLNR expression. Knockdown of APLN (AKD) in these GSCs and subsequent orthotopic implantation in mice massively reduced the GBM vascularisation, as compared to tumours generated by control GSCs. Injection of AKD-GSCs into APLN-knockout mice further normalised the intratumoural vascular network to a level otherwise observed in the tumour-free brain. Infusion of the APLNR-agonist apelin-13 restored angiogenesis in APLN-deficient tumours. In stereotactic biopsies of GBM patients we found an upregulation of APLNR in the tumour infiltrative zone (lacking aberrant vascularisation), which points towards an additional role for APLNR in tumor cells. In a series of cell culture and in vivo experiments we observed that autocrine APLN signalling promotes GSC-invasion. Importantly, application of an APLNR antagonist was able to block both tumour angiogenesis and GBM cell invasion in vivo. In summary, we show that APLN-APLNR signalling induces GBM neo-vascularization as well as GSC-invasion and that both pathological features are blunted by APLNR-blockade. We propose APLNR inhibition as a new strategy for combined anti-angiogenic and anti-invasive GBM treatment, which may provide therapeutic benefits for a broad range of GBM subsets.
Infections gastro-intestinales chez les touristes : quelle responsabilité ?
Authors: R Cartwright
Journal: Eurosurveillance (2004)

Les progres dans le domaine de la sante publique et du controle des maladies transmissibles en Europe ont ete possibles non seulement grâce aux efforts des medecins de sante publique mais egalement grâce a une approche multidisciplinaire. Les resultats de l'equipe espagnole (1) qui a investigue l'epidemie de gastro-enterite chez des touristes en Republique Dominicaine sont une bonne illustration de la necessite d'une cooperation entre disciplines et entre pays. Sur le plan mondial, le tourisme fait partie des trois forces economiques les plus importantes, le nombre de touristes ne cessant de croitre chaque annee. On estime a plus de 70 millions par an le nombre de voyages organises vendus en Europe toutes destinations confondues. Les touristes sont ainsi exposes a une variete d'environnements et d'organismes pathogenes.
P3.01-087 Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC as Third-Line Treatment: Data from Trial ALTER 0303
Authors: K. Li, J. Wang, B. Han, Y. Zhao, Q. Wang, L. Zhang, J. Shi, Z. Wang, J. He, Y. Shi, Y. Cheng, W. Chen, X. Wang, Y. Luo, K. Nan, F. Jin, J. Dong, B. Li, Y. Chen, J. Zhou, D. Wang, X. Zhou, Y. Yu, L. Chen, A. Liu, J. Huang, C. Huang, B. Cao, J. Chen, R. Ma, Z. Yu, C. Ding, H. Wang
Journal: Journal of Thoracic Oncology (2017)
TMIC-37. THE MICROENVIRONMENT OF A YOUNGER BRAIN IS MORE PERMISSIVE FOR BREAST CANCER BRAIN METASTASIS
Authors: Alex Man Lai Wu, Emma Dolan, Brunilde Gril, Christina Robinson, Simone Difilippantonio, Lalage Wakefield, Patricia Steeg
Journal: Neuro-Oncology (2017)

Brain metastases are the most common tumors in the brain. Women diagnosed with breast cancer at a relatively young age have a higher risk of developing brain metastases and will often have a poorer outcome compared to women diagnosed at older age. We hypothesized that the brain microenvironment of young breast cancer patients promotes the formation of brain metastases. To test this hypothesis, we injected brain-seeking human triple negative MDA-MB-231BR breast cancer cells into the left-cardiac ventricle of young and old mice. We then compared metastatic tumor burden at study endpoint by quantifying the number of metastases in hematoxylin & eosin stained brain tissue sections. Consistent with our hypothesis, young mice developed two-fold (p<0.05) more brain metastases compared to older mice, and the metastases that developed were larger. Importantly, this effect of age was not model-specific, since young Balb/c mice injected with brain-seeking mouse triple negative 4T1-BR breast cancer cells also developed significantly (p<0.05) more brain metastases compared to older mice. Immunohistochemical analysis of the MDA-MB-231BR brain metastases revealed that there was similar level of Ki67 expression and GFAP-expressing reactive astrocytes between the two age cohorts. To further test whether this effect of age extends to other metastatic sites, we injected mouse (6DT1, HRM1, E0771, MVT1) and human (MDA-MB-231) breast cancer cells either orthotopically into the mammary fat pad or directly into the circulation of young and old mice. Age had no effect on metastatic burden in these models where the primary metastatic site is the lungs. Together, the data support our hypothesis that the age of the brain microenvironment can influence metastasis development, and suggest that the effect of age may depend on the metastatic site. Future work will aim to gain mechanistic insight into this phenomenon, with the goal that it may translate to age-specific therapies.
Uma estratégia para melhorar e avaliar a cobertura vacinal no norte de Portugal
Authors: G Gonçalves, M A Frutuoso, M C Ferreira, M G Freitas
Journal: Eurosurveillance (2005)

Na area sanitaria do norte de Portugal, a cobertura vacinal foi medida a partir de registos individuais (previamente verificados) de vacinacao dos centros de cuidados. Cada ano entre 2001 e 2004, coortes por data de nascimento (criancas de mais de 2, 6 ou 14 anos) foram seleccionadas para a avaliacao. Os dados eram recolhidos en janeiro do ano seguinte, em seguida cada mes de marco reunioes eram organizadas com os coordinadores de vacinacao por distrito. As coberturas vacinais observadas no norte de Portugal eram otimas, para todas as vacinas e coortes de nascimento consideradas. No artigo seguinte fazemos comparacoes com os dados da literatura internacional sobre a cobertura vacinal e discutimos sobre a validade dos resultados. Acreditamos que os nossos dados de coberturas vacinais nao sofrem de bies serios, embora comparacoes com dados internacionais devem ser feitas com cautela. Os metodos utilizados contribuiram a melhorar a cobertura vacinal.
P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient with EGFR TKI Drug Resistance
Authors: S. Xu, X. Liu, R. Liu, T. Shi, X. Li, D. Zhong, Y. Wang, G. Chen, J. Chen
Journal: Journal of Thoracic Oncology (2017)
Guías BICHAT para el manejo clínico de la peste y de la peste relacionada con el bioterrorismo
Authors: P Bossi, A Tegnell, A Baka, F van Loock, A Werner, J Hendriks, H Maidhof, G Gouvras
Journal: Eurosurveillance (2004)

Yersinia pestis es uno de los principales agentes bacterianos que pueden utilizarse para ataques bioterroristas. El uso de una forma aerosolizada de este agente puede producir un gran brote de peste neumonica primaria. Las bacterias tambien pueden
EGFR mutational status in determining choice of TKIs or standard chemotherapy for patients with advanced non-small cell lung cancer
Authors: L. Motta, G. Motta, G. Banna, F. Martorana, C. Longhitano, N. Inzerilli, N. Restuccia, M. Aiello, H.J. Soto Parra, P. Vigneri
Journal: Annals of Oncology (2017)
Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne
Authors: Diane M. Thiboutot, Brigitte Dréno, Abdullah Abanmi, Andrew F. Alexis, Elena Araviiskaia, Maria Isabel Barona Cabal, Vincenzo Bettoli, Flordeliz Casintahan, Steven Chow, Adilson da Costa, Tam El Ouazzani, Chee-Leok Goh, Harald P.M. Gollnick, Minerva Gomez, Nobukazu Hayashi, Maria Isabel Herane, Juan Honeyman, Sewon Kang, Lajos Kemeny, Raj Kubba, Julien Lambert, Alison M. Layton, James J. Leyden, Jose Luis López-Estebaranz, Nopadon Noppakun, Falk Ochsendorf, Cristina Oprica, Beatriz Orozco, Montserrat Perez, Jaime Piquero-Martin, Jo-Ann See, Dae Hun Suh, Jerry Tan, Vicente Torres Lozada, Patricia Troielli, Leihong Flora Xiang
Journal: Journal of the American Academy of Dermatology (2017)
Gadolinium Presence Within Cutaneous Sclerotic Bodies Confirmed by Laser Ablation Inductively Coupled Plasma Mass Spectrometry
Authors: Justin P. Bandino, Robert M. Gathings, Harriet B. Hinen, Marta T. Hampton, W. Clay Davis, Dirk M. Elston
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
QLIF-22. MAINTENANCE OF HEALTH RELATED QUALITY OF LIFE (QOL) BEYOND PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB
Authors: Katherine B Peters, Mary Lou Affronti, Stevie Threatt, Patrick Healy, James E Herndon, Eric S Lipp, Sujata Panta, Dina Randazzo, Henry S Friedman, Annick Desjardins
Journal: Neuro-Oncology (2017)

Newly diagnosed GBM patients experience challenges to maintain their health related QoL throughout the disease course. Disease- and treatment-related factors impact health related QoL. We sought to evaluate the trajectory of health related QoL in newly diagnosed glioblastoma patients treated with bevacizumab at diagnosis, through the disease course, and beyond progression. In this prospective single-center study, newly diagnosed subjects with GBM were treated with concurrent radiation and temozolomide plus bevacizumab followed by adjuvant temozolomide and bevacizumab. At progression, bevacizumab use was continued but chemotherapy could be changed per the treating neuro-oncologist recommendation. Health related QoL was evaluated using the Functional Assessment of Cancer Therapy-Brain (FACT-Br) at time of study enrollment (before chemoradiation), after chemoradiation, and then every 6 mos until study discontinuation or subject demise. Higher scores on the FACT-Br correspond to better QoL. 68 newly diagnosed GBM patients were enrolled with a mean age of 55.4 yrs (sd=10.7 yrs). KPS ranged 70-100 with the following distribution: 70 (n=4), 80 (n=28), 90 (n=34), and 100 (n=2). FACT-Br scores were relatively maintained from baseline evaluation (mean=96.71, sd=17.64) to 20 months from baseline (mean=100.68, sd=22.12). Subjects who continued study participation 6 mos after the completion of chemoradiation were divided into two groups: subjects with (n=16) and without (n=35) tumor progression 6 mos after chemoradiation completion. Regardless of disease progression, both groups maintained QoL (with progression baseline (mean=98.06, sd=17.18) and 14 months from baseline (mean=91.80, sd 7.16) and without progression baseline (mean=96.34 sd=17.09) and 14 months from baseline (mean=96.75, sd=24.95)). Our observations of health related QoL throughout the disease course and beyond progression suggest that health related QoL can be maintained in GBM patients treated with bevacizumab. Continued evaluation of health related QoL throughout the disease course is warranted in the evaluation of novel treatment regimens in GBM.
DDIS-19. NOVEL PEPTIDE HOMING TO GLIOMA-SPECIFIC ISOFORM OF BREVICAN SELECTIVELY TARGETS MALIGNANT BRAIN TUMORS
Authors: Choi-Fong Cho, Yarah Ghotmi, Colin Fazden, Justin Wolfe, Fernanda Bononi, Emily Murrell, Leonard Luyt, Mariano Viapiano, Bradley Pentelute, E Antonio Chiocca, Sean E Lawler
Journal: Neuro-Oncology (2017)

High-grade gliomas are deadly cancers, and current standard-of-care has demonstrated limited success. The ability to specifically target glioma cells can allow for the development of safer and more efficacious brain cancer therapy strategies. Brevican (BCAN), a CNS-specific extracellular matrix protein is upregulated in glioma cells and its expression correlates with tumor progression. Particularly, a membrane-bound BCAN isoform lacking normal glycosylation, called B/bΔg is a unique glioma marker and is not expressed in non-cancerous tissues. Therefore, B/bΔg represents a valuable target for anti-cancer strategies. Here, we describe the utilization of state-of-the-art technologies that we have recently developed to discover novel "B/bΔg-Targeting Peptides" (BTP). Briefly, small magnetic beads displaying B/bΔg were used to screen a one-bead-one-compound combinatorial library, enabling high-throughput labeling of library beads presenting peptide candidates with high affinity for B/bΔg. The "hit" beads were rapidly sorted using a microfluidic magnetic-activated sorter of our own design. The hits were then, exposed to cells expressing B/bΔg, and beads with the highest cell association were isolated and sequenced. Characterization of the purified peptides through kinetic binding analysis and cell uptake studies revealed BTP-7 as the lead candidate for B/bΔg binding. BTP-7 displayed 260 nanomolar affinity for recombinant B/bΔg protein, and had little association with the fully glycosylated isoform of BCAN. Scrambling of the BTP-7 sequence led to complete abrogation of B/bΔg binding. For in vivo evaluation, GBM-6 tumors derived from human patients were established intracranially in nude mice, and tumor formation was verified by MRI. Upon systemic administration, BTP-7 displayed approximately 10x greater binding to GBM-6 tumors than the control, as well as 4x higher tumor uptake compared to normal brain tissue. We are currently working on conjugating BTP-7 to a variety of toxic payload to selectively target gliomas, with the goal of improving brain cancer therapeutic efficacy that can ultimately benefit patient.
P2.02-004 Gene Mutational Feature in Lung Enteric Adenocarcinoma by the Next Generation Sequencing
Authors: W. Wang, C. Xu, L. Lin, W. Zhuang, Y. Shao, Y. Tai, R. Chen, Y. Guan, X. Yi, Y. Chen, M. Wu, G. Chen
Journal: Journal of Thoracic Oncology (2017)
Surveillance de la varicelle et de l’herpès zoster en Slovénie, 1996-2005
Authors: M Socan, M Blaško
Journal: Eurosurveillance (2007)

En Slovenie, la varicelle et l’herpes zoster sont des maladies a declaration obligatoire. Cet article presente les donnees de surveillance couvrant une periode de dix ans, de 1996 a 2005. Les taux d’incidence de la varicelle variaient entre 456 et 777 par 100 000 dans tous les groupes d’âge. Jusqu’a 75% des cas de varicelle rapportes etaient des enfants en âge pre-scolaire, les plus touches etant les enfants de trois a quatre ans. L’incidence de la varicelle augmentait entre octobre et janvier, les taux les plus faibles etant observes en aout et septembre ; cette variation saisonniere coincidant avec le calendrier scolaire. Depuis 1995, l’herpes zoster est une maladie a declaration obligatoire. En 2005, 1627 cas ont ete notifies (81,3 sur 100 000), avec plus de cas chez les femmes que chez les hommes. La tranche d’âge la plus touchee etait les plus de 70 ans. Les complications, telles que la meningite zosterienne ou la meningo-encephalite, ont ete rares (3,05 cas declares/1 million de cas).
Abstract 19681: The Combination of Allogeneic Mesenchymal Stem Cells and Cardiac Stem Cells Produce Synergistic Effects in Cardiac Regeneration
Authors: Makoto Natsumeda, Victorea Florea, Angela M Castellanos, Bryon A Tompkins, Ana M Landin, Julia Fritsch, Kevin Collon, Louis Vincent, Anthony J Kanelidis, Jose Rodriguez, Marcos Rosado, Ivonne H Schulman, Wayne Balkan, Raul Mitrani, Joshua Hare
Journal: Circulation (2016)

Introduction: Combining mesenchymal stem cells (MSCs) and cardiac stem cells (CSCs) has synergistic effects in reducing scar size and improving cardiac function for the treatment of ischemic cardio...
NRP2 and CD63 Are Host Factors for Lujo Virus Cell Entry
Authors: Matthijs Raaben, Lucas T. Jae, Andrew S. Herbert, Ana I. Kuehne, Sarah H. Stubbs, Yi-ying Chou, Vincent A. Blomen, Tomas Kirchhausen, John M. Dye, Thijn R. Brummelkamp, Sean P. Whelan
Journal: Cell Host & Microbe (2017)
P3.01-051 Dramatic Response to Afatinib in EGFR-Mutant Lung Adenocarcinomas After Resistance to First-Generation EGFR Inhibitors: A Brief Report
Authors: W.-. Li, J.-. Yang, H.-. Chen, A.-. Li, J.-. Lin, H.-. Tu, J. Su, X.-. Zhang, Y. Wu
Journal: Journal of Thoracic Oncology (2017)